5.86

1.18% -0.07

Pre-market: 5.80 -0.06 -1.02%

Gyre Therapeutics Inc (GYRE)

Overview News Price History Why GYRE Down? Discussions Forecast

Gyre Therapeutics Inc stock is traded at $5.86, with a volume of 57,131. It is down -1.18% in the last 24 hours and down -10.53% over the past month. Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Previous Close:

$5.93

Open:

$5.95

24h Volume:

57,131

Relative Volume:

0.62

Market Cap:

$568.59M

Revenue:

$117.05M

Net Income/Loss:

$-3.71M

P/E Ratio:

-75.22

EPS:

-0.0779

Net Cash Flow:

$1.67M

1W Performance:

-3.14%

1M Performance:

-10.53%

6M Performance:

-22.28%

1Y Performance:

-26.66%

1-Day Range:

$5.81

$6.09

1-Week Range:

$5.81

$6.34

52-Week Range:

$5.44

$9.42

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name

Gyre Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(858) 284-0115

Address

12730 HIGH BLUFF DRIVE, SAN DIEGO

Employee

618

Twitter

Next Earnings Date

2026-05-08

Latest SEC Filings

GYRE's Discussions on Twitter

Compare GYRE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GYRE Gyre Therapeutics Inc	5.86	568.59M	117.05M	-3.71M	1.67M	-0.0779
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	Jefferies	Buy
Aug-26-25	Initiated	H.C. Wainwright	Buy
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Jan-04-19	Initiated	Oppenheimer	Outperform
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy

View All

Gyre Therapeutics Inc Stock (GYRE) Latest News

06:30 AM

Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion - Stock Titan

06:30 AM

Jun 15, 2026

Gyre COO Ye Weiguo sells $17,276 in company stock - Investing.com

Jun 15, 2026

Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options - Stock Titan

Jun 15, 2026

Jun 13, 2026

GYRE Q1 2026 Earnings: EPS Surprises to the Upside, Revenue Not Reported, Stock SlipsForward EPS Estimate - newsline.com

Jun 13, 2026

Jun 11, 2026

Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock - Investing.com UK

Jun 11, 2026

Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock By Investing.com - Investing.com South Africa

Jun 11, 2026